GoKawiilAlgonquin trial tests BPd combination in relapsed multiple myeloma across nine Canadian sites
Researchers report interim results from the ongoing Algonquin study, a multicentre, open-label trial evaluating a BPd drug combination in patients with relapsed or refractory multiple myeloma. The analysis covers patients enrolled in the trial's second phase, with data collected through late October 2025 after enrollment closed in September 2022. Eligible patients had failed prior treatments including lenalidomide and proteasome inhibitors, but had not previously received pomalidomide or BCMA-targeted therapy.
GoKawiil's interpretation of the reporting above, not reported fact.
Multiple myeloma remains largely incurable, and patients who become refractory to standard drugs like lenalidomide face limited options. This trial's design—testing a new combination in a carefully defined relapsed population—could inform whether BPd offers a viable next-line therapy for a hard-to-treat patient group.
- The Algonquin trial is a multicentre Canadian study testing a BPd regimen in relapsed/refractory multiple myeloma.
- Enrollment focused on patients who had failed lenalidomide and proteasome inhibitors but were naive to pomalidomide and BCMA therapies.
- Interim data reflects outcomes through October 2025 for patients enrolled by September 2022, following an initial dose-finding phase.
Source: nature.com — St. Paul, 2026-09-16
Published there as: “Identification of broadly tumour-reactive γδ TCRs from multiple myeloma”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.